

ONE HUNDRED SIXTEENTH CONGRESS
Congress of the United States
House of Representatives
COMMITTEE ON ENERGY AND COMMERCE
2125 RAYBURN HOUSE OFFICE BUILDING
WASHINGTON, DC 20515-6115
Majority (202) 225-2927
Minority (202) 225-3641

May 10, 2019

Ms. Kathleen Tregoning
Executive Vice President for External Affairs
Sanofi
55 Corporate Drive
Bridgewater, NJ 08807

Dear Ms. Tregoning:

Thank you for appearing before the Subcommittee on Oversight and Investigations on Wednesday, April 10, 2019, at the hearing entitled "Priced out of Lifesaving Drugs: Getting Answers on the Rising Cost of Insulin." We appreciate the time and effort you gave as a witness before the Subcommittee on Oversight and Investigations.

Pursuant to Rule 3 of the Committee on Energy and Commerce, members are permitted to submit additional questions to the witnesses for their responses, which will be included in the hearing record. Attached are questions directed to you from members of the Committee. In preparing your answers to these questions, please address your responses to the member who has submitted the questions using the Word document provided with this letter.


To facilitate the publication of the hearing record, please submit your responses to these questions by no later than the close of business on Friday, May 24, 2019. As previously noted, this transmittal letter and your responses, as well as the responses from the other witnesses appearing at the hearing, will all be included in the hearing record. Your responses should be transmitted by e-mail in the Word document provided with this letter to Jourdan Lewis, Policy Analyst with the Committee, at jourdan.lewis@mail.house.gov. You do not need to send a paper copy of your responses to the Committee. Using the Word document provided for submitting your responses will also help maintain the proper format for incorporating your answers into the hearing record.

Ms. Kathleen Tregoning

Page 2

Thank you for your prompt attention to this request. If you need additional information or have other questions, please contact Ms. Lewis at (202) 225-2927.

Sincerely,


Frank Pallone, Jr.
Chairman

Attachments

cc: Hon. Greg Walden, Ranking Member
Committee on Energy and Commerce

Hon. Diana DeGette, Chair
Subcommittee on Oversight and Investigations

Hon. Brett Guthrie, Ranking Member
Subcommittee on Oversight and Investigations

**Committee on Energy and Commerce
Subcommittee on Oversight and Investigations**

**Hearing on
“Priced Out of Lifesaving Drugs: Getting Answers on the Rising Cost of Insulin”**

April 10, 2019

Ms. Kathleen Tregoning, Executive Vice President for External Affairs, Sanofi

The Honorable Joseph P. Kennedy III (D-MA)

1. At the Oversight Subcommittee hearing on April 2, 2019, the witnesses spoke about the ineffectiveness of patient assistance programs and testified the programs are untimely, unworkable, and a barrier to accessing insulin. Whether the programs' criteria are too difficult to find or the application processes require already sick people to jump through hoops, there is wide consensus the programs are a cruel substitute for lower list prices.

Regarding patient assistance programs specifically for insulin at your company, please provide a clearer picture of how they operate by answering the following questions.

- a. Where can patients find information on eligibility and criteria for the programs?
 - b. What are the eligibility criteria for the programs?
 - c. What information and documents must patients submit in order to qualify for the programs?
 - d. What number of patients apply for the programs each year, what number are approved, and what number are denied?
 - e. What are the ten most common reasons your company denies a patient's application?
 - f. Once a patient qualifies for a program, how often must the patient reapply or recertify? How long does the approval last?
 - g. How much did your company spend on public awareness campaigns to promote the patient assistance program in 2018? How much did your company spend on advertising for insulin in 2018?
2. Regarding patient assistance programs at your company for all types of medication, please provide a clearer picture of how they operate by answering the following questions.
 - a. Where can patients find information on eligibility and criteria for the programs?

- b. What are the eligibility criteria for the programs?
 - c. What information and documents must patients submit in order to qualify for the programs?
 - d. What number of patients apply for the programs each year, what number are approved, and what number are denied?
 - e. What are the ten most common reasons your company denies a patient's application?
 - f. Once a patient qualifies for a program, how often must the patient reapply or recertify? How long does the approval last?
 - g. How much did your company spend on public awareness campaigns to promote the patient assistance program in 2018? How much did your company spend on advertising for medication in 2018?
3. Are there any medications not on your company's patient assistance program? Please provide a list of the drugs that are available for patient assistance and those that are not a part of patient assistance programs.
 4. Does your company make medication available to patients for free or reduced prices, or does it use a private foundation or other third parties to operate patient assistance programs? When your company makes contributions of medication to private foundations, such as Sanofi's Patient Connection, Sanofi's Foundation for North America, Novo Nordisk's NovoCare, Eli Lilly's Lilly Cares, or other third parties, does your company correspondingly reduce its tax liability? Please provide the amount by which your company reduced its tax liability for 2018 as a result of making contributions to patient assistance programs.

The Honorable Nanette Díaz Barragán (D-CA)

1. Sanofi has filed 74 patent applications on Lantus, and more than 90 percent of these were filed after the drug was already approved and on the market. I'm concerned that these patents are not related to innovative improvements to the drug, but are part of Sanofi's strategy to further delay competition and retain control of this market.

Please explain the innovative nature of these patents filed after the approval of Lantus, and why they merit additional exclusivity to the detriment of diabetes patients?

The Honorable Brett Guthrie (R-KY)

1. There have been press reports about a letter that one Pharmacy Benefit Manager (PBM), OptumRx, sent to pharmaceutical manufacturers requesting that pharmaceutical manufacturers provide the PBM with notice if the manufacturer decides to lower the list price

of the medicine. Has Sanofi received a letter from any PBMs or insurers requesting that it provide the PBM or insurer with notice before Sanofi lowers the list price of insulin or any other medicine? If so, please list the entities that have sent such a letter to Sanofi and describe the requirements set forth in the letter.

- a. Does Sanofi have any contractual obligations to provide a supply chain partner with notice before lowering the list price of insulin or any other medicine? If so, please list the entities and describe the contractual provisions.
 - b. Has Sanofi provided any of its supply chain partners with notice of a list price decrease? If so, please describe these interactions.
 - c. What happens to Sanofi's rebate obligations with PBMs if Sanofi lowers the list price of insulin or any other medicine?
 - d. Has the letter sent by OptumRx or any other similar requests by supply chain partners impacted Sanofi's decisions regarding whether to lower the list price of insulin or any other medicine? If so, please describe.
2. In Sanofi's testimony, Sanofi notes that the average net price of Sanofi's most prescribed insulin, Lantus, has declined by over 30 percent since 2012 while the average out-of-pocket burden for patients with commercial insurance and Medicare has increased by approximately 60 percent over that same period. Which factor described in Sanofi's testimony (e.g., list price, increase in number of high deductible health plans, changes in insurance design, changes to drug formularies, etc.) has had the greatest impact on the out-of-pocket burden for patients using insulin?
3. According to a November 2018 I-MAK report on Lantus, 74 patent applications have been filed on Lantus and 95 percent of the patent applications on Lantus were filed after the drug was first approved and on the market in 2000.¹ Is this correct, and if so, why did Sanofi file these patent applications after the drug was first approved and on the market?
 - a. How many of the patents relating to Lantus are on the insulin drug substance and how many are on the delivery device?
 - b. How many potentially competing products for Lantus has Sanofi challenged because of the existing patents on Lantus?
 - c. What impact, if any, did these patent applications have on the launch of Basaglar?
4. Eli Lilly launched a follow-on insulin product—Basaglar—in 2016 to compete with Lantus. What impact, if any, has the launch of Basaglar had on the list price and net price of Lantus?

¹ I-MAK, Overpatented, Overpriced: Lantus (Nov. 1, 2018), *available at* <https://www.i-mak.org/lantus/>.

5. We have heard that for many insulin products, the net price the manufacturer receives for the insulin products has been decreasing. For example, in Sanofi's testimony, Sanofi said that, between 2012 and 2018, the average aggregate net price across all Sanofi insulin products has declined by 25 percent while the list price has increased by 126 percent. Manufacturers have said that they oftentimes increase list prices to provide greater rebates and obtain formulary placement for their product. On the other hand, we have heard from many PBMs that PBMs typically prefer the product with the lowest net price when there are competing products available—such as generic medicines or therapeutically equivalent alternatives. It therefore is not clear why manufacturers continue to increase the list price of insulin and provide greater rebates for these products rather than simply reducing the list price. Please explain.
6. During the hearing, the witnesses were asked about administrative fees paid by manufacturers to PBMs and how these administrative fees are oftentimes a percentage of the wholesale acquisition cost (WAC)—or list price—of a medicine.
 - a. What are the advantages and disadvantages of having administrative fees that are a percentage of the WAC, or list price, of a medicine?
 - b. Does your company support moving to a system where administrative fees are based on a flat fee instead?

The Honorable Jeff Duncan (R-SC)

1. One thing that we heard from patients and doctors last week is that insulin hasn't changed much, so they don't understand why the price keeps going up. In testimony from the hearing, however, the manufacturers described their significant research and development efforts to improve the treatment options available for patients with diabetes. For example, Eli Lilly described some of the improvements with modern insulin. Similarly, Novo Nordisk noted that in just the last few years they have developed new drugs like Tresiba and Fiasp and have also created new, more accurate and convenient delivery systems. Further, Sanofi noted that their innovations in diabetes, and specifically for insulin, have been significant and diabetes continues to be an area of focus for their research and development efforts.

Yet, testimony from one of the Pharmacy Benefit Managers (PBMs) implied almost the complete opposite stating that there is a lack of innovation and therefore a lack of competition. OptumRx's testimony stated that "[i]nsulin has been used to treat diabetes for nearly 100 years, and "manufacturers have not introduced any significant new innovations, yet they continue to drive list prices higher and extend their patents."

So, which is it? Is there innovation in the insulin market or not?

2. One thing that we've heard may be a barrier to innovation and competition are patents. Eli Lilly's testimony noted that "[n]one of the active ingredients in Lilly's insulin products are

covered by an active patent. There are few generic insulins on the market because insulin is complicated and expensive to produce and safely distribute as a refrigerated product."

Yet, OptumRx's testimony states that "[f]or years, insulin manufacturers have used loopholes in the patent system to stifle competition. One manufacturer has filed 74 patents on one of its brands to prevent competition. Others have engaged in multi-year patent disputes to delay the introduction of lower-cost products."

So, which is it? Are there patents preventing innovation and competition or not?